The Wyoming Department of Health is conducting a survey concerning the use and barriers to use of 17-alpha hydroxyprogesterone in pregnant women. If you routinely provide prenatal care for your pregnant patients, please participate in this survey.
The Draft 2016 PDL is available for review. Please submit comments before January 1, 2016.
Preferred Drug List (PDL)
The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org.
A new policy for public comment at meetings is effective December 2, 2012.
PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)
Public Guidelines and Public Comment Request Form (updated November 5, 2015)
The following prior authorization criteria were approved at the August 11, 2016 P & T Committee meeting.
Epclusa will be preferred for treatment of Hepatitis C. Class criteria applied to all Hepatitis C treatments can be found at http://www.wymedicaid.org/pa.
Zinbryta will be non-preferred in the multiple sclerosis category, requiring trial and failure of two agents from different classes. This requirement is in line with its labeled indication as it has significant safety concerns requiring a REMS program.
Nuplazid and Xiidra will be limited to indication.
Comments may be sent by email to email@example.com or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY 82071. Comments should be received prior to October 1, 2016.
Agenda November 10, 2016
Minutes August 11, 2016
Thursday, February 11; Wednesday, May 11; Thursday, August 11; Thursday, November 10
All meetings are at 10 am at Laramie County Community College. Please see agenda for room location.